Skip to main content

Table 2 Bivariate analysis of categorical variables associated with the cognition scores

From: Clinical and genetic factors associated with self-reported cognitive deficits in women with breast cancer: the “CAGE-Cog” study

Variable

CogPCI Mean ± SD

CogPCA Mean ± SD

CogOTH Mean ± SD

CogQOL Mean ± SD

Total FACT-Cog Mean ± SD

Education

  Primary

57.19 ± 18.53

22.28 ± 5.95

13.12 ± 3.79

10.37 ± 5.35

102.97 ± 29.90

  Secondary

57.26 ± 13.68

22.08 ± 5.19

13.13 ± 3.23

9.52 ± 4.71

102.00 ± 23.34

  University

55.58 ± 13.68

24.88 ± 5.82

13.51 ± 2.85

10.78 ± 4.63

104.76 ± 21.96

  p

0.535

0.063

0.884

0.390

0.588

Marital status

  Single/ widowed/ divorced

56.00 ± 14.44

24.62 ± 5.01

13.83 ± 2.23

11.66 ± 4.56

106.12 ± 22.12

  Married

57.12 ± 14.33

22.68 ± 5.62

13.18 ± 3.32

9.71 ± 4.80

102.70 ± 23.42

  p

0.632

0.315

0.712

0.09

0.803

Diabetes

  No

57.77 ± 13.88

23.19 ± 5.44

13.44 ± 3.07

10.18 ± 4.68

104.59 ± 22.47

  Yes

49.27 ± 16.41

21.18 ± 6.54

11.82 ± 3.79

8.63 ± 5.85

90.90 ± 26.79

  p

0.042

0.456

0.116

0.350

0.052

Metastasis

  No

56.87 ± 14.29

22.99 ± 5.64

13.34 ± 3.18

10.30 ± 4.84

103.50 ± 23.35

  Yes*

57.88 ± 15.26

23.12 ± 4.64

12.50 ± 3.16

6.50 ± 2.07

100.00 ± 21.67

  p

0.730

0.821

0.311

0.022

0.568

Type of chemotherapy

  Palliative regimen

57.88 ± 15.26

23.12 ± 4.64

12.50 ± 3.16

6.50 ± 2.07

100.01 ± 21.67

  Adjuvant treatment

58.47 ± 12.96

23.65 ± 5.27

13.78 ± 2.70

11.00 ± 4.63

106.90 ± 20.73

  Neo-adjuvant treatment

51.47 ± 17.46

20.89 ± 6.48

11.79 ± 4.11

7.75 ± 4.74

91.90 ± 28.28

  p

0.282

0.144

0.046

0.001

0.038

Vinorelbine intake**

  No

57.00 ± 14.08

22.99 ± 5.64

13.27 ± 3.19

10.17 ± 4.80

103.44 ± 23.13

  Yes

55.26 ± 21.98

23.25 ± 2.50

13.50 ± 3.11

6.00 ± 2.83

98.01 ± 26.75

  p

0.826

0.950

0.949

0.08

0.616

Doxorubicin intake**

  No

56.06 ± 15.28

22.80 ± 5.85

13.01 ± 3.29

9.70 ± 4.84

101.58 ± 24.44

  Yes

59.99 ± 9.77

23.68 ± 4.40

14.24 ± 2.52

11.16 ± 4.54

109.07 ± 17.14

  p

0.430

0.839

0.072

0.212

0.188

ABCB1 rs1045642

  CC

56.08 ± 10.25

23.85 ± 4.18

14.09 ± 2.40

8.85 ± 4.50

102.89 ± 13.07

  CT

57.18 ± 15.64

22.94 ± 5.94

13.21 ± 3.30

10.15 ± 4.70

103.49 ± 25.26

  TT

56.29 ± 15.08

22.27 ± 5.65

12.92 ± 3.44

10.29 ± 5.14

101.78 ± 25.37

  p

0.625

0.765

0.412

0.525

0.755

COMT rs4680

  VV

55.00 ± 14.17

22.61 ± 5.55

13.28 ± 3.62

9.48 ± 5.10

100.39 ± 23.91

  VM

57.85 ± 15.13

22.77 ± 5.92

13.56 ± 2.88

10.00 ± 4.67

104.18 ± 24.58

  MM

57.22 ± 12.07

23.90 ± 4.99

12.91 ± 3.05

10.50 ± 4.86

104.54 ± 18.28

  p

0.463

0.492

0.556

0.799

0.512

DRD2 rs6277

  CC

53.50 ± 14.42

23.00 ± 5.61

12.41 ± 3.69

8.70 ± 5.01

97.62 ± 25.12

  CT

57.10 ± 16.08

22.62 ± 5.68

13.55 ± 3.32

9.79 ± 4.68

103.07 ± 24.75

  TT

59.46 ± 10.08

23.21 ± 5.14

13.84 ± 2.33

10.71 ± 4.51

107.22 ± 16.80

  p

0.359

0.859

0.485

0.335

0.387

OPRM1 rs179971

  AA

56.29 ± 14.93

22.84 ± 5.62

13.29 ± 3.31

9.30 ± 4.83

101.73 ± 24.27

  AG

58.70 ± 11.50

23.39 ± 5.43

13.34 ± 2.67

12.56 ± 3.72

108.01 ± 17.81

  p

0.743

0.519

0.671

0.005

0.296

CLOCK rs1801260

  TT

56.04 ± 14.20

22.68 ± 6.10

13.05 ± 3.38

10.28 ± 4.77

102.06 ± 24.14

  TC

56.77 ± 14.67

22.90 ± 5.93

13.36 ± 3.24

9.73 ± 4.85

102.77 ± 23.72

  CC

64.00 ± 14.73

23.33 ± 3.05

16.00 ± 0.00

10.33 ± 5.50

113.67 ± 23.16

  p

0.625

0.934

0.103

0.823

0.694

PER2 rs934945

  GG

55.85 ± 14.89

22.90 ± 5.97

13.58 ± 3.18

10.03 ± 5.10

102.37 ± 24.30

  GA

57.42 ± 13.12

22.73 ± 4.71

12.79 ± 3.23

9.89 ± 4.23

102.84 ± 20.97

  AA

66.75 ± 13.37

26.00 ± 6.48

13.50 ± 2.51

10.00 ± 5.88

116.25 ± 25.55

  p

0.248

0.590

0.283

0.975

0.513

CRY2 rs10838524

  GG

55.77 ± 13.81

22.80 ± 5.97

13.32 ± 3.22

9.79 ± 4.84

101.70 ± 23.38

  AG

57.77 ± 14.28

23.27 ± 5.30

13.38 ± 2.79

10.32 ± 4.67

104.74 ± 2.55

  AA

56.56 ± 16.03

22.39 ± 5.48

13.05 ± 4.20

9.47 ± 5.24

101.49 ± 27.87

  p

0.793

0.917

0.969

0.796

0.865

  1. Numbers in bold are significant results (p < 0.05)
  2. *Patients with metastasis were not considered as having a relapsed breast cancer (thus not excluded) because they had a primary diagnosis of metastatic breast cancer
  3. **Other treatment types (chemotherapy and non-chemotherapy) did not give significant results